New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 17, 2014
09:21 EDTHITK, AKRXAkorn completes acquisition of Hi-Tech Pharmacal for $640M in cash
Akorn (AKRX) announced that it has completed its previously announced acquisition of Hi-Tech Pharmacal (HITK) for $640M in cash. The combination of Akorn and Hi-Tech will transform the company into a larger, more diversified generic player.
News For AKRX;HITK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 27, 2015
17:51 EDTAKRXS&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices
Subscribe for More Information
17:22 EDTAKRXUnited Insurance to replace Akorn in S&P 600 as of 1/30 close
17:21 EDTAKRXAkorn to replace Protective Life in S&P 400 as of 1/30 close
Subscribe for More Information
January 26, 2015
07:05 EDTAKRXAkorn price target raised to $55 from $45 at Piper Jaffray
Piper Jaffray raised its price target for Akorn shares to $55 saying approvals of "seemingly minor" abbreviated New Drug Application opportunities, like last week's Phenylephrine Hydrochloride Ophthalmic Solution, could in the aggregate drive significant upside to consensus estimates in 2015 and beyond. Piper reiterates an Overweight rating on shares of Akorn.
January 20, 2015
08:09 EDTAKRXAkorn price target raised to $49 from $44 at Jefferies
Jefferies raised its price target for Akorn shares to $49 to reflect its FY15 estimates. The firm keeps a Buy rating on the stock.
07:11 EDTAKRXAkorn receives FDA approval for Phenylephrine Hydrochloride Ophthalmic Solution
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use